Flagellin enhances tumor-specific CD8+ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model

Vaccine

Volumn 31, Issue 37, 2013, Pages 3879-3887

  Nguyen, Chung Truong ^a   Hong, Seol Hee ^a   Sin, Jeong Im ^b   Vu, Hong Van Dinh ^a   Jeong, Kwangjoon ^a,c   Cho, Kyoung Oh ^a   Uematsu, Satoshi ^d   Akira, Shizuo ^e   Lee, Shee Eun ^a   Rhee, Joon Haeng ^a,c  

^a Chonnam National University   (South Korea)

^b Kangwon National University   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d UNIVERSITY OF TOKYO   (Japan)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

Adjuvant; Cancer; Flagellin; TLR5; Vaccine

Indexed keywords

ADJUVANT; CANCER VACCINE; FLAGELLIN; GAMMA INTERFERON; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN E6; PROTEIN E7; TOLL LIKE RECEPTOR 5; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; DRUG POTENTIATION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LUNG TUMOR; LYMPH NODE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN; VIBRIO VULNIFICUS;

ADJUVANT; CANCER; FLAGELLIN; TLR5; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLAGELLIN; HUMANS; INTERFERON-GAMMA; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 5; VACCINES, SYNTHETIC;

EID: 84881558642     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.054     Document Type: Article

References (44)

1. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410(6832):1099-1103.
2. Smith K.D., Andersen-Nissen E., Hayashi F., Strobe K., Bergman M.A., Barrett S.L.R., et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003, 4(12):1247-1253.
3. Lee S.E., Kim S.Y., Jeong B.C., Kim Y.R., Bae S.J., Ahn O.S., et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 2006, 74(1):694-702.
4. Lee S., Koh Y., Kim M.-K., Kim Y., Kim S., Nam J., et al. Inhibition of airway allergic disease by co-administration of flagellin with allergen. J Clin Immunol 2008, 28(2):157-165.
5. Nguyen C.T., Kim S.Y., Kim M.S., Lee S.E., Rhee J.H. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 2011, 29(34):5731-5739.
6. Hong S.H., Byun Y.H., Nguyen C.T., Kim S.Y., Seong B.L., Park S., et al. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine 2012, 30(2):466-474.
7. Burdelya L.G., Krivokrysenko V.I., Tallant T.C., Strom E., Gleiberman A.S., Gupta D., et al. An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008, 320(5873):226-230.
8. Rhee S.H., Im E., Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 2008, 135(2):518-528.
9. Sfondrini L., Rossini A., Besusso D., Merlo A., Tagliabue E., Menard S., et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 2006, 176(11):6624-6630.
10. Cai Z., Sanchez A., Shi Z., Zhang T., Liu M., Zhang D. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 2011, 71(7):2466-2475.
11. Frazer I.H. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004, 4(1):46-55.
12. Fernando G.J., Murray B., Zhou J., Frazer I.H. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin Exp Immunol 1999, 115(3):397-403.
13. Kim T.Y., Myoung H.J., Kim J.H., Moon I.S., Kim T.G., Ahn W.S., et al. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res 2002, 62(24):7234-7240.
14. Cui Z., Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: Therapeutic effect against cervical cancer. Cancer Immunol Immunother 2005, 54(12):1180-1190.
15. Pre'ville X., Ladant D., Timmerman B., Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 2005, 65(2):641-649.
16. Feltkamp M.C.W., Smits H.L., Vierboom M.P.M., Minnaar R.P., De Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993, 23(9):2242-2249.
17. Muderspach L., Wilczynski S., Roman L., Bade L., Felix J., Small L.A., et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000, 6(9):3406-3416.
18. Zwaveling S., Ferreira Mota S.C., Nouta J., Johnson M., Lipford G.B., Offringa R., et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002, 169(1):350-358.
19. Manuri P.R., Nehete B., Nehete P.N., Reisenauer R., Wardell S., Courtney A.N., et al. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 2007, 25(17):3302-3310.
20. Bae S.H., Park Y.-J., Park J.-B., Choi Y.S., Kim M.S., Sin J.-I. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res 2007, 13(1):341-349.
21. Lin K.-Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996, 56(1):21-26.
22. Seo S.H., Kim K.S., Park S.H., Suh Y.S., Kim S.J., Jeun S.S., et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 2011, 18(5):488-495.
23. Huang B., Zhao J., Li H., He K.-L., Chen Y., Mayer L., et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005, 65(12):5009-5014.
24. Uematsu S., Fujimoto K., Jang M.H., Yang B.G., Jung Y.J., Nishiyama M., et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol 2008, 9(7):769-776.
25. Uematsu S., Jang M.H., Chevrier N., Guo Z., Kumagai Y., Yamamoto M., et al. Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol 2006, 7(8):868-874.
26. Seo S.H., Jin H.T., Park S.H., Youn J.I., Sung Y.-C. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine 2009, 27(42):5906-5912.
27. Yu Y.A., Shabahang S., Timiryasova T.M., Zhang Q., Beltz R., Gentschev I., et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004, 22(3):313-320.
28. Sharma R.K., Schabowsky R-H., Srivastava A.K., Elpek K.G., Madireddi S., Zhao H., et al. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res 2010, 70(10):3945-3954.
29. Munn D.H., Mellor A.L. The tumor-draining lymph node as an immune-privileged site. Immunol Rev 2006, 213:146-158.
30. Sin J.-I. MyD88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model. Vaccine 2011, 29(24):4125-4131.
31. Huang C.-H., Peng S., He L., Tsai Y.-C., Boyd D.A.K., Hansen T.H., et al. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther 2005, 12(15):1180-1186.
32. Sin J.-I., Kim J.-M., Bae S.H., Lee I.H., Park J.S., Ryoo H.M. Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. Mol Ther 2009, 17(5):906-913.
33. Miretti S., Roato I., Taulli R., Ponzetto C., Cilli M., Olivero M., et al. A mouse model of pulmonary metastasis from spontaneous osteosarcoma monitored in vivo by luciferase imaging. PLoS ONE 2008, 3(3):e1828.
34. Ikeda H., Old L.J., Schreiber R.D. The roles of IFN[gamma] in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002, 13(2):95-109.
35. Ji H., Chang E.Y., Lin K.-Y., Kurman R.J., Pardoll D.M., Wu T.C. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 1998, 78(1):41-45.
36. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2(8):675-680.
37. Hedayat M., Takeda K., Rezaei N. Prophylactic and therapeutic implications of toll-like receptor ligands. Med Res Rev 2012, 32(2):294-325.
38. Akira S. Innate immunity and adjuvants. Philos Trans R Soc Lond B Biol Sci 2011, 366(1579):2748-2755.
39. Faham A., Altin J.G. Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect. J Immunol 2010, 185(3):1744-1754.
40. Garaude J., Kent A., van Rooijen N., Blander J.M. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 2012, 4(120):120ra16.
41. Bijker M.S., van den Eeden S.J., Franken K.L., Melief C.J., Offringa R., van der Burg S.H. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 2007, 179(8):5033-5040.
42. Melief C.J. Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine. J Immunother 2012, 35(3):215-216.
43. Hung C.-F., Cheng W.-F., Hsu K.-F., Chai C.-Y., He L., Ling M., et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001, 61(9):3698-3703.
44. Suk Kim M., Sin J.-I. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology 2005, 116(2):255-266.